Objectives: This study investigated the trend in antimicrobial resistance among group B Streptococcus (GBS) from a national surveillance programme in Taiwan and delineated characteristics of and factors associated with levofloxacin-resistant isolates.
Introduction
Group B Streptococcus (GBS), also named Streptococcus agalactiae, can be found as part of the normal flora in the gastrointestinal tract, genital tract, perineal, periurethral and perianal areas, and even the upper respiratory tract. 1 GBS is associated with neonatal sepsis and invasive infections in adults with certain predisposing conditions, particularly advanced age, malignancy and diabetes. [2] [3] [4] Implementation of intrapartum chemoprophylaxis strategies since 2002 has led to a substantial decline in neonatal GBS infections. 4, 5 In contrast, invasive GBS diseases in adults represent an increasing burden worldwide. [2] [3] [4] 6 In Taiwan, obstetricians have also become increasingly aware of the importance of antenatal GBS screening over time. The antenatal GBS screening rate increased from 10% in 2004 to 65% in 2008 at a medical centre with a concurrent decreased rate of GBS as an aetiological agent of neonatal early-onset sepsis. 7 To decrease neonatal GBS diseases, the health authority launched a national programme to provide free culture-based GBS screening for low-income pregnant women and for all pregnant women starting in 2010 and 2012, respectively, hence GBS screening became a routine obstetric practice thereafter. 8 Penicillin is the first-line drug for the treatment of GBS infections, while erythromycin, clindamycin, vancomycin and fluoroquinolones are important alternatives for those who are allergic to penicillin. 9, 10 Therefore, monitoring of resistance to these agents in each region is important. High rates of resistance to clindamycin and erythromycin have been reported from different regions but data on inducible clindamycin resistance are not always V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
included. [10] [11] [12] Isolates with reduced penicillin susceptibility have also been reported from Japan, 13 and vancomycin-resistant isolates, albeit rare, have also been found. 14 Fluoroquinoloneresistant GBS strains have also emerged in the past decade, especially in Asia, including China, Japan and Korea. 9, 10, 12, 13, 15, 16 Although molecular characterizations of fluoroquinolone-resistant GBS isolates have been reported from different countries, data on fluoroquinolone-resistant GBS are limited in Taiwan and factors associated with fluoroquinolone resistance in GBS have not been well described.
The Taiwan Surveillance of Antimicrobial Resistance (TSAR) is a longitudinal, multicentre, hospital-based national surveillance programme of clinical isolates from all sample types and patient groups to monitor antimicrobial resistance trends and detect emerging resistance. 17 In light of the changing epidemiology of GBS and increasing antimicrobial resistance, the present study aimed to: (i) investigate the trend of antimicrobial resistance in GBS from 2002 to 2012 in the TSAR collection to ensure appropriate treatment and intrapartum chemoprophylaxis; and (ii) delineate clinical and molecular characteristics of levofloxacin-resistant isolates for a better understanding of the genetic backgrounds of and factors associated with resistant strains to aid in implementing control strategies.
Materials and methods

Isolate collection and identification
GBS isolates were collected as part of the TSAR programme from July to September biennially between 2002 (TSAR III) and 2012 (TSAR VIII). The isolates were from a total of 28 hospitals, 24 of which participated in all six rounds of TSAR. The hospitals are located in all four regions of Taiwan and included 12 medical centres and 15 regional hospitals. One local hospital also participated in TSAR VIII. The collection protocol was similar for all six rounds of TSAR. In each hospital, the following isolates were collected sequentially first without specifying bacterial species: 50 outpatient isolates, 30 adult ICU and 100 non-ICU inpatient isolates and 20 paediatric isolates. After completion of the above collection, an additional 20 (for 2002, 2004 and 2006) to 50 (for 2008, 2010 and 2012) isolates from blood and sterile body sites were collected, again without specifying bacterial species. In 2010 and 2012, because of its increasing clinical significance, we asked the hospitals to collect all GBS isolates during the collection period. All isolates were stored at #80 C. Demographic data on isolates provided by the hospitals included patient age, specimen type and patient location [ICU, non-ICU inpatient and outpatient/emergency room (OPD)]. The isolates were recovered from clinical samples taken as part of standard care and the TSAR project was approved by the Research Ethics Committee of National Health Research Institutes, Taiwan (EC960205 and EC1010602-E). Identification of GBS was based on colony morphology, b-haemolysis, negative bacitracin (Taxo TM A discs) susceptibility, a positive CAMP (Cristie/Atkins/Munch-Peterson) test and a positive latex agglutination test (Oxoid, Basingstoke, UK).
Antimicrobial susceptibility
MICs were determined by broth microdilution (BMD) using Sensititre standard panels (Trek Diagnostics, East Grinstead, UK). The test conditions and interpretation of results followed the recommendations and breakpoints of CLSI. 18 Ceftriaxone, cefepime, erythromycin, levofloxacin, meropenem, penicillin and tetracycline were tested on isolates from all study years. Cefotaxime, linezolid and vancomycin were not tested in 2002. Clindamycin and daptomycin were tested on isolates from 2010 and 2012.
Isolates that were clindamycin susceptible and erythromycin resistant were tested for inducible clindamycin resistance by the double disc diffusion test (D-test) and those that were D-test-positive are defined as clindamycin resistant. 18 All levofloxacin-non-susceptible isolates were also classified as having an iMLS B or cMLS B (inducible or constitutive macrolidelincosamide-streptogramin B resistant) or M (macrolide resistant only) phenotype.
Characterization of levofloxacin-nonsusceptible isolates
All levofloxacin-non-susceptible isolates were characterized by capsular polysaccharide serotypes using a multiplex PCR method, 19 PFGE 20 and underlying resistance determinants, including mutations in the QRDRs of gyrA and parC 21 and the presence of macrolide resistance genes erm(A), erm(B) and mef(A), 22 using previously published primers and protocols with slight modifications for PFGE. Briefly, for PFGE, isolates were grown on 5% sheep blood agar plates at 35 C under 5% CO 2 for 24 h, with subsequent plug preparation, bacterial cell lysis (without mutanolysin) and washing following published procedures. 20 After digestion with 30 U of SmaI at 25 C for 3 h in CutSmart buffer (NEB, New England Biolabs Inc., Ipswich, MA, USA), the DNA fragments were separated in 0.5 % Tris-Borate-EDTA buffer at 14 C for 22 h with a voltage of 6 V/cm at fixed angle of 120 and pulse times ranging from 5 to 40 s by CHEF Mapper (Bio-Rad Laboratories, Richmond, CA, USA). PFGE patterns were analysed using BioNumerics software (Version 4.61, Applied Maths NV, Sint-Martens-Latem, Belgium). Cluster analysis was performed and dendrograms were prepared by the unweighted pair group method with arithmetic averages (UPGMA) with the Jaccard coefficient. Pulsotypes were assigned to clusters of isolates having 80% similarity in PFGE patterns based on the dendrogram. MLST was performed on selected isolates of each PFGE pulsotype following standard MLST protocol (http://pubmlst.org/sagalactiae/). 23 
Statistical analysis
Antimicrobial susceptibility was analysed using the WHONET software with isolates from 2002-06 and 2008-12 grouped as early and late periods, respectively. 24 All statistical analyses were performed with the Statistical Package for the Social Sciences version 17.0 (SPSS, Chicago, IL, USA). Univariate and multivariate logistic regression analyses were conducted to examine factors associated with isolation of levofloxacin-non-susceptible isolates. A P value ,0.05 was considered statistically significant and all tests were two-tailed.
Results
Bacterial isolates
A total of 1559 GBS isolates were studied and their demographic data are provided in Table S1 (available as Supplementary data at JAC Online). Most (64.5%) isolates were from outpatients and the majority (92.2%) were from adults, including one-third (32.3%) from the elderly (.65 years old). Urine (29.1%) and female genital tract (26.3%) samples constituted the largest proportions, followed by abscess or pus (16.4%), blood (15.8%) and respiratory tract (8.9%) samples. Compared with the early period, more isolates were collected in the later period, with a higher proportion of isolates from the female genital tract. In 2010 and 2012, 72 and 182 isolates were from samples from antenatal GBS screening, respectively. Excluding these 254 isolates from antenatal screening, the early and late study periods had a comparable sample type distribution and proportions of isolates from adult patients (Table S2) .
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Antimicrobial susceptibility
Penicillin, cefotaxime, ceftriaxone, cefepime, meropenem, daptomycin and vancomycin remained active against all tested isolates. All but one of the tested isolates were susceptible to linezolid. Nonsusceptibility to tetracycline (84%) was high but decreased in the later study period (92.5% in 2002-06 versus 82.3% in 2008-12; P , 0.001), while non-susceptibility to erythromycin remained similar between the two study periods (46.9% in 2002-06 versus 42.5% in 2008-12; P " 0.212). Non-susceptibility to clindamycin, which was tested on all isolates in 2010 and 2012 only, was 39.9%. Ten of the 69 clindamycin-susceptible and erythromycinnon-susceptible isolates from the 1266 GBS isolates in 2010 and 2012 were positive for inducible clindamycin resistance. Among the 254 isolates from antenatal screening, 37.0% and 35.8% were non-susceptible to erythromycin and clindamycin, respectively, the latter of which included 7 isolates that were inducible clindamycin resistant. The secular trend of antimicrobial susceptibility to clindamycin, erythromycin, levofloxacin and tetracycline between 2002 and 2012 can be seen in Figure 1 .
The rate of levofloxacin non-susceptibility was 5.6% overall but was significantly higher in 2008-12 (6.2%) than in 2002-06 (2.2%) (P " 0.016). In addition, the overall levofloxacin non-susceptibility differed in isolates from different specimen types and age groups, such as 0% in non-respiratory isolates from paediatric patients, 2.8% in female genital tract isolates (which included those from antenatal screening) and 27.4% in respiratory isolates from elderly patients ( Figure 2 ). The majority (81, 92%) of the levofloxacin-nonsusceptible isolates had a high levofloxacin MIC (32 mg/L), while another five isolates had a levofloxacin MIC in the 6-16 mg/L range and only two had intermediate resistance (MIC 4 mg/L). We therefore refer to these levofloxacin-non-susceptible isolates as levofloxacin resistant hereafter. By study year, no levofloxacinresistant GBS isolates were detected in 2002, but were detected in isolates from 5 hospitals in 2004-06 and from 20 hospitals located in all four regions of Taiwan in 2008-12.
Molecular characterization of levofloxacin-resistant GBS isolates
Among the 88 levofloxacin-resistant isolates, serotype III was most prevalent (38, 43.1%), followed by serotypes VI (25, 28.4%), II (16, 18 .2%), 1b (7, 8 .0%) and V (2, 2.3%) ( Table 1) . Serotype III isolates were widely distributed in different regions and most were recovered from ,65-year-old adult outpatients and from urine and female genital tract specimens. In particular, all eight levofloxacin-resistant isolates from antenatal screening belonged to serotype III (Figure 2 ). Isolates of serotypes II and VI were mostly from respiratory and urine samples, from elderly inpatients (including those in ICUs) and from central and northern regions.
All 88 levofloxacin-resistant isolates had two or more amino acid substitutions in the QRDRs of gyrA and parC (Table 1 and Figure 3 ). The majority (70, 79.5%) had the GyrA(S81L)!ParC(S79F/Y) double mutations, which were found in 85.7%, 100% and 92.0% of serotype Ib, III and VI isolates, respectively. A minority (14, 15.9%) of isolates had the GyrA(S81L) ! ParC(S80P) mutations with or without the additional ParC(D83Y/G) mutation, which was detected in 81.4% of serotype II isolates. The remaining four isolates had the GyrA(S81L) ! ParC(D83Y), GyrA(S81L) ! ParC(S79Y and S80P), GyrA (E85K) ! ParC(S79F) and GyrA(E85Q) ! ParC(S79F) mutations. Levofloxacin-resistant GBS in Taiwan 
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.32 Wu et al. Figure 3 . Dendrogram of 88 levofloxacin-resistant GBS isolates based on SmaI-digested PFGE patterns. Strains were clustered by UPGMA and dice coefficient with tolerance set at 1.0% and optimization at 3%. Pulsotypes (A-J) were assigned to isolates having 80% similarity in PFGE patterns if there were three or more isolates in that cluster; O, other pulsotypes distinct from A-K. Isolate: the first four digits indicate isolation year, followed by region [C (central), N (northern), E (eastern), S (southern)]; the next two digits are the hospital number, and the last three digits are the isolate number. GyrA and ParC: amino acid changes in the QRDRs of the GyrA (gyrase A) and ParC (par C) subunits of topoisomerase II and IV, respectively.
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A total of 61 (69.3%), 56 (63.8%) and 74 (84.1%) of the levofloxacin-resistant isolates were also non-susceptible to erythromycin, clindamycin and tetracycline, respectively, and the majority were MDR, with 54 isolates (61.4%) being non-susceptible to both erythromycin and tetracycline, 48 (54.5%) of which were also clindamycin non-susceptible. Nearly all of the serotype Ib, II, III and VI isolates (59, 96.7%) had the cMLS B phenotype and carried erm(B), including 8 isolates of serotype III that carried both erm(B) and mef(A). The remaining two isolates (serotype III) had the M phenotype and carried mef(A) ( Table 1) .
Based on PFGE, 61 of the levofloxacin-resistant isolates could be grouped into 11 pulsotypes (A-K) (isolates with .80% similarity in PFGE patterns) ( Table 1 and Figure 2) . The pulsotypes within the main serotypes were diverse, especially the serotype III isolates, which contained pulsotypes A-E as well as several other distinct pulsotypes. However, isolates of the same serotype tended to cluster closer together overall. MLST was conducted on 50 isolates selected from different pulsotypes. Of the 24 serotype III isolates on which MLST was conducted, 23 (96%) were associated with ST19 (22 isolates) or its single-locus variant (SLV) ST921 (1 isolate). ST19/serotype III isolates clustered into five different pulsotypes plus several distinct pulsotypes and were found in different regions of Taiwan from diverse sample types, including those from antenatal screening (Figure 3) . ST1 was associated with two serotypes, II and VI, but several isolates of serotype VI were SLVs of ST1, i.e. ST920 and ST922. ST10 and ST12 (an SLV of ST10) were associated with serotype Ib (Table 1 and Figure 3) . ST920, ST921 and ST922 are new STs that had not been found previously and have been deposited in the MLST database.
Collectively, most isolates within the same PFGE cluster had similar QRDR mutation patterns and erythromycin and tetracycline resistance profiles. Nevertheless, some isolates within the same pulsotype carrying different QRDR mutation or erythromycin and tetracycline resistance profiles were seen, such as those in D, H, G and J pulsotypes (Table 1 and Figure 2 ). Of note, most isolates from earlier years (2004, 2006, 2008) , albeit few in number, had pulsotypes and STs distinct from each other, whereas isolates from the later period tended to fall into clusters. Emergence of some clones with regional transmission was observed in pulsotypes G (ST1/serotype VI), H (ST1/serotype II), I (ST920/serotype VI) and J (ST922/serotype VI), which were detected only from 2010 on. These pulsotypes contained several isolates having indistinguishable or highly similar PFGE patterns and the isolates were either from the same hospital or from different hospitals in the same region and from different study years.
Factors associated with levofloxacin-resistant GBS
Multivariate analysis revealed that .65-year-old patients, respiratory samples and later study years were three independent factors associated with levofloxacin resistance both for all isolates (Table 2 ) and for the subset of isolates excluding those from antenatal screening (Table S3) .
Discussion
This nationwide longitudinal survey included 1559 GBS consecutive isolates during collection months between 2002 and 2012. All isolates remained susceptible to penicillin, cephalosporins, meropenem and vancomycin. However, rates of resistance to erythromycin (42.5%), clindamycin (39.9%) and tetracycline (82.3%) remained high and the rate of levofloxacin resistance increased over time. Our data indicated that b-lactams and vancomycin remain the antibiotics for primary or alternative treatment or intrapartum prophylaxis of GBS infections in Taiwan. Linezolid and daptomycin, two newer agents with potent anti-Gram-positive activity, were also active against all isolates studied in 2010-12 (except one isolate that was linezolid non-susceptible), consistent with the low resistance rates reported elsewhere, 25 and hence could be considered as alternative therapeutic choices.
Although the rates of resistance to erythromycin (42.5%) and clindamycin (39.9%) in our GBS were lower than those reported in China (71.2%-85.7% for erythromycin and 53.4%-73.2% for clindamycin), 10,15 they were similar to those found in the USA, 11, 26 and much higher than that reported from Brazil (,4.1%). 3 Of note, over one-third of the isolates from antenatal screening were resistant to clindamycin, supporting the recommendation of conducting clindamycin susceptibility testing on antenatal GBS isolates from women with penicillin allergy. 5 Due to the high prevalence of resistance found here (83.5%) and in most countries (.81%), tetracycline would not be suitable for empirical treatment of GBS infections. 3, 10, 15, 27 Rates of levofloxacin resistance in GBS varied in different countries, from 1.4% in Italy to 18.4% in Japan, 32.7% in Korea and 37%-39% in China. 9, 10, 15, 16, 28 Our longitudinal survey indicated that levofloxacin resistance in GBS emerged around 2004 in Taiwan then increased to 6.2% during 2008-12. This is also evident by multivariate analysis showing that the late period was an independent risk factor associated with levofloxacin resistance. Furthermore, the rising resistance rate could not be attributed to a larger number of isolates from antenatal screening during the late period, since these isolates had a lower resistance rate than the overall resistance rate during the contemporary period. Although our overall levofloxacin resistance rate was lower than those of the neighbouring Asian countries, the majority of our levofloxacin-resistant isolates had high-level levofloxacin resistance (MIC .32 mg/L). The most common QRDR mutation profile of our levofloxacin-resistant isolates, GyrA(S81L) ! ParC(S79F/Y) double mutations, has been reported previously.
9,10,12 However, we also detected a few previously unreported point mutations. In streptococci, fluoroquinolone resistance usually arises from spontaneous mutations in QRDRs of gyrA and parC, and the resistant mutants are then selected by fluoroquinolone exposure. 29 The initial selection may be augmented by later clonal transmission and both contribute to increased prevalence of resistance. 29 A large proportion of our levofloxacin-resistant GBS isolates belonged to ST19/serotype III (43.2%). Clonal expansion of ST19/ serotype III was found to be the primary cause of the high prevalence of fluoroquinolone-resistant GBS in China, 10, 15 whereas, in Italy most fluoroquinolone-resistant isolates belonged to ST19/ serotype Ib. 9 Our ST19/serotype III isolates were found in different regions of Taiwan from diverse sample types, including antenatal screening samples. Fluoroquinolones are not typically used for pregnant women, which made resistance development less likely in this population. Additionally, these isolates were mostly recovered from outpatients and middle-aged adults, the population who were expected to have less exposure to fluoroquinolones compared with the elderly and inpatients. Therefore, it is possible that individuals were colonized or infected by extant Wu et al.
fluoroquinolone-resistant ST19/serotype III isolates circulating in the community.
Of note, ST19/serotype III isolates from Taiwan and China shared similar molecular and phenotypic characteristics: both had the GyrA(S81L) ! ParC(S79Y) double mutations, most also carried erm(B) conferring resistance to erythromycin and clindamycin, and most were resistant to tetracycline. 10 Due to the close geographical proximity and frequent travel between China and Taiwan, it is also possible that some MDR ST19/serotype III strains have disseminated in China and Taiwan. Monitoring of its future global spread may be warranted.
Nearly half of our levofloxacin-resistant GBS isolates belonged to four novel genotypes (ST/serotype combination): ST1/serotype II, ST1/serotype VI, ST1-SLV (ST920)/serotype VI and ST1-SLV (ST922)/serotype VI. Although both serotypes had the same GyrA(S81L) mutation, their ParC mutation profiles differed, with S80P for serotype II and S79(F/Y) for serotype VI isolates. To date, the ParC(S80P) mutation has only been reported in one GBS strain from Japan, 12 and no GyrA(S81L) ! ParC(S80P) mutations have been reported. A nosocomial outbreak of serotype VI levofloxacinresistant GBS has been reported from Japan but the organisms belonged to ST458, an SLV of ST1. 30 Our ST1-SLVs (ST920 and ST922) are two new variants distinct from ST458. The finding of ST1 and its SLV fluoroquinolone-resistant GBS isolates with different serotypes and QRDR mutation profiles from different countries suggested that these resistant strains have evolved from separate local strains.
These ST1/serotype II, ST1/serotype VI, ST1-SLV (ST920)/serotype VI and ST1-SLV (ST922)/serotype VI isolates were mostly recovered from central and northern regions of Taiwan and from urine and respiratory specimens of hospitalized elderly patients, including those from ICUs. Elderly patients in ICU settings are more frequently associated with infectious diseases and subsequent antibiotic exposure. Within each serotype, several of the isolates from the same hospital or from different hospitals in the same region shared highly similar or indistinguishable PFGE patterns, indicating possible intra-hospital and inter-hospital spread. These data suggested that ST1/serotype II and ST1, ST920 and ST922/ serotype VI levofloxacin-resistant isolates may have emerged through spontaneous mutation of endogenous strains under Levofloxacin-resistant GBS in Taiwan JAC selective pressure, which then spread within the healthcare facility and region. 29, 31, 32 A recent study in Japan observed that most of the GBS isolates with reduced susceptibility to both penicillin and levofloxacin were recovered from respiratory specimens of elderly patients. 13 In this study, we further confirmed that respiratory samples and elderly patients are two independent factors associated with levofloxacin resistance in GBS. The average amount of quinolone consumed during 2002-09 in Taiwan was about 7 million DDDs per year. 33 Respiratory and urinary tract infections are the major infectious diseases in the elderly, for which fluoroquinolones are commonly prescribed. In vivo selection of a levofloxacin-resistant GBS mutant from the sputum of a patient treated with levofloxacin for bronchitis 32 and co-isolation of fluoroquinolone-resistant Haemophilus influenzae and GBS from patients with antecedent fluoroquinolone exposure have been reported. 31 Recently, increasing levofloxacin resistance was observed among H. influenzae clinical isolates and those colonizing long-term care facility residents in Taiwan. 34, 35 Taking these results together, it is speculated that the occurrence of fluoroquinolone-resistant GBS, particularly ST1/serotype II, ST1/serotype VI, ST1-SLV (ST920)/serotype VI and ST1-SLV (ST922)/serotype VI, in Taiwan might be the adverse consequence of widespread fluoroquinolone use, especially for respiratory illness in elderly patients. To halt the rise of fluoroquinolone resistance in common community pathogens, a governmental policy against inappropriate fluoroquinolone use has been implemented since 2008 through the National Health Insurance system in Taiwan, and the amount of quinolone usage decreased thereafter. 33 Resistance trends should continue to be monitored to evaluate the effects of the intervention .
Our study has some limitations. First, clinical data on GBS isolates are not available so that their clinical significance is unclear with regard to isolates from non-sterile sites. Second, the isolate collection protocols differed between the two periods. Although the multivariate adjustment and subgroup analysis excluding isolates from antenatal screening can compensate for the differences, potential confounding factors not included in the statistics may exist. Third, the ST/serotype distribution of all isolates is not demonstrated so other prevalent clones may have been missed. For example, isolates of ST17, a prevalent clone associated with neonatal infections, were not found here. 36 This is likely because ST17 isolates from China and Korea were usually levofloxacin susceptible and our characterization of resistant isolates only would not identify ST17 isolates if they were susceptible. 15, 16 In conclusion, this nationwide longitudinal study revealed multiclonal occurrence and spread of levofloxacin-resistant GBS isolates, with ST19/serotype III being the most common, but four novel genotypes, ST1/serotype II, ST1/serotype VI, ST1-SLV (ST920)/serotype VI and ST1-SLV (ST922)/serotype VI, also being found. Emergence of resistance and clonal expansion likely both contributed to the increased prevalence of resistance. In light of recent reports of increasing fluoroquinolone resistance in different bacterial species in Taiwan, 34, 37 this study further underlines the importance of monitoring fluoroquinolone use and reducing transmission opportunities. Continuous molecular-level surveillance should also be carried out concurrently to ensure appropriate chemoprophylaxis and treatment, and to detect emerging resistant clones.
